Can I read EE233 Cost-Effectiveness of Ravulizumab Compared with Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in the Netherlands on EtoBox?

EE233 Cost-Effectiveness of Ravulizumab Compared with Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in the Netherlands by S Quist; AJ Postma; KJ Myren; L de Jong; MJ Postma is a scholarly article available to read on EtoBox.

What is EE233 Cost-Effectiveness of Ravulizumab Compared with Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in the Netherlands about?

This study evaluated the healthcare resource utilization in relapsing remitting multiple sclerosis patients with highly active disease. Methods: Adult patients with $1 medical claim for MS diagnosis (G35/340) and $1 claim for a DMT were identified from a deidentified administrative claims database (between 1 Jan 2014 and 30 Sep 2019). Patients must have been continuously enrolled in a health plan (medical and pharmacy) for at least 1-year pre-and 1-year post-index (index: first MS claim). Overall and MS-related cost (both plan and patient paid) along with relapse burden were descriptively analyzed for 1-year post-index. Results: Of the 54,545 patients with $1 medical claim for MS and DMT, 11,407 were eligible for this study. Majority of patients were females (75%) and aged $40 years (77%). Approximately 30% of patients had one or more relapse during 1-year post index. The most commonly used DMTs both 1-year pre-and post-index were glatiramer acetate (41% and 28%), followed by dimethyl fumarate (19% and 26%), interferon Beta-1a (16% and 17%). Overall cost per patient during the 1-year post index was $72,718. MS-related cost per patient was 86% of overall cost

Author

S Quist; AJ Postma; KJ Myren; L de Jong; MJ Postma

Publisher

Elsevier BV

Published

2022

Language

EN